aminocaproic acid has been researched along with Embolism, Pulmonary in 15 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We then evaluated the patients' hemoglobin, hematocrit, activated thromboplastin time, international normalized ration, fibrinogen, and thrombocyte count and symptoms of pulmonary embolism." | 3.73 | The role of antifibrinolytic agents in gynecologic cancer surgery. ( Aypar, U; Canbay, O; Celebi, N; Celebioglu, B; Karagoz, AH; Selcuk, M, 2006) |
| "One hundred consecutive patients treated with epsilon aminocaproic acid 24 grams daily prior to surgery for ruptured intracranial aneurysms have been compared with the previous 100 patients managed similarly but without anti-fibrinolytic drugs." | 3.66 | Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. ( Ameen, AA; Illingworth, R, 1981) |
| " Deep vein thrombosis (DVT) can lead to pulmonary embolism (PE), but the mechanisms responsible for this progression are unknown." | 1.51 | Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. ( Gani, DM; Gross, PL; Kim, PY; Shaya, SA; Weitz, JI, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, C | 3 |
| Ma, J | 3 |
| Xu, J | 3 |
| Wu, L | 3 |
| Wu, Y | 3 |
| Liu, Y | 3 |
| Shen, B | 3 |
| Li, M | 1 |
| Liu, Q | 1 |
| Geng, P | 1 |
| Shi, L | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Roy, KM | 1 |
| Rajan, GR | 1 |
| Shaya, SA | 1 |
| Gani, DM | 1 |
| Weitz, JI | 1 |
| Kim, PY | 1 |
| Gross, PL | 1 |
| STUDER, A | 2 |
| REBER, K | 1 |
| LOREZ, HP | 2 |
| DOUGLAS, AS | 2 |
| MCNICOL, GP | 2 |
| BROWSE, NL | 1 |
| JAMES, DC | 1 |
| Celebi, N | 1 |
| Celebioglu, B | 1 |
| Selcuk, M | 1 |
| Canbay, O | 1 |
| Karagoz, AH | 1 |
| Aypar, U | 1 |
| Moser, KM | 1 |
| Ameen, AA | 1 |
| Illingworth, R | 1 |
| Levati, A | 1 |
| Minella, C | 1 |
| Farina, ML | 1 |
| D'Angelo, V | 1 |
| Sopher, M | 1 |
| Braunfeld, M | 1 |
| Shackleton, C | 1 |
| Busuttil, RW | 1 |
| Sangwan, S | 1 |
| Csete, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for aminocaproic acid and Embolism, Pulmonary
| Article | Year |
|---|---|
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon-Aminocaproic Acid to Reduce Bleeding in TKA: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
THROMBOLYTIC THERAPY.
Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Biomedical Research; Deoxyribonuclease I; Drug Th | 1964 |
Thromboembolic disease in the patient undergoing urologic surgery.
Topics: Aminocaproic Acid; Anticoagulants; Clothing; Dextrans; Heparin; Humans; Postoperative Complications; | 1983 |
10 other studies available for aminocaproic acid and Embolism, Pulmonary
| Article | Year |
|---|---|
Reversal of ε-Aminocaproic Acid-Induced Massive Thromboemboli Using Tissue Plasminogen Activator During Cardiac Surgery: A Case Report.
Topics: Aminocaproic Acid; Coronary Artery Bypass; Humans; Male; Middle Aged; Pulmonary Embolism; Tissue Pla | 2019 |
Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi.
Topics: Aminocaproic Acid; Animals; Anticoagulants; Antifibrinolytic Agents; Blood Platelets; Cells, Culture | 2019 |
[EXPERIMENTAL STUDY ON THE PROBLEM OF THE SIGNIFICANCE OF INTRAVASCULAR FIBRIN FORMATION IN THE OCCURRANCE OF ARTERIOSCLEROTIC CHANGES IN THE WALLS OF BLOOD VESSELS].
Topics: Aminocaproates; Aminocaproic Acid; Animals; Arteriosclerosis; Fibrin; Fibrinolysis; Glycosuria; Hema | 1964 |
THROMBOLYTIC THERAPY.
Topics: Aminocaproates; Aminocaproic Acid; Deoxyribonuclease I; Fibrinolysin; Fibrinolysis; Pharmacology; Ph | 1964 |
STREPTOKINASE AND PULMONARY EMBOLISM.
Topics: Aminocaproates; Aminocaproic Acid; Biomedical Research; Blood Coagulation Tests; Deoxyribonuclease I | 1964 |
[INFLUENCE OF EPSILON-AMINOCAPROIC ACID ON THE PULMONARY VASCULAR CHANGES FOLLOWING INTRAVENOUS THROMBIN INFUSIONS IN RABBITS].
Topics: Aminocaproates; Aminocaproic Acid; Animals; Injections; Injections, Intravenous; Lagomorpha; Pharmac | 1965 |
The role of antifibrinolytic agents in gynecologic cancer surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Colloids; Crystalloid Solutions; Fema | 2006 |
Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Child; Female; | 1981 |
Potential hazards of antifibrinolytic treatment in subarachnoid haemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Coronary Disease; Humans; Male; Middle Aged; Pulmonary Embolism; | 1980 |
Fatal pulmonary embolism during liver transplantation.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Hepatitis C; Humans; Liver Cirrhosis; | 1997 |